Statins in rheumatology

Joint Bone Spine

Volumn 73, Issue 2, 2006, Pages 159-168

  Soubrier, Martin ^a   Roux, Christian ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b René Descartes Hospital ^*  (France)

Author keywords

Atheroma; Osteoporosis; Rheumatoid arthritis; Statins

Indexed keywords

ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CLODRONIC ACID; ETIDRONIC ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ATHEROMA; BONE METABOLISM; DRUG MECHANISM; FRACTURE; HUMAN; MORBIDITY; MORTALITY; MYALGIA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 33645305976     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2005.04.008     Document Type: Short Survey

References (99)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. J. Sheperd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. MacFarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 1998;339:1349-57.
4. Heart Protection Study Collaborative Group MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
5. G.G. Schwartz, A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Olivier, and D. Waters Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
6. J.P. Halcox, and J.E. Deanfield Beyond the laboratory. Clinical implications for statin pleiotropy Circulation 109 Suppl II 2004 42 48
7. S.R. Cummings, and D.C. Bauer Do statins prevent both cardiovascular disease and fracture? JAMA 283 2000 3255 3257
8. I.B. McInnes, D.W. McCarrey, and N. Sattar Do statins offer therapeutic potential in inflammatory arthritis? Ann. Rheum. Dis. 63 2004 1535 1537
9. P. Duriez Mechanisms of actions of statins and fibrate Therapie 58 2003 5 14
10. A.S. Wierzbicki, R. Poston, and A. Ferro The lipid and non-lipid effects of statins Pharmacol. Ther. 99 2003 95 112
11. R.G. Russell, M.J. Rogers, J.C. Frith, S.P. Luckman, F.P. Coxon, and H.L. Benford The pharmacology of biphosphonates and new insights into their mechanisms of action J. Bone Miner. Res. 14 1999 53 65
12. A.A. Reszka, J.M. Halasy-Nagy, P.J. Masarachia, and G.A. Rodan Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis: a link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase J. Biol. Chem. 274 1999 34967 34973
13. G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, and G. Rossini Stimulation of bone formation in vitro and in rodents by statins Science 286 1999 1946 1949
14. T. Maeda, A. Matsunuma, I. Kurahashi, T. Yanagawa, H. Yoshida, and N. Horiuchi Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells J. Cell Biochm. 92 2004 458 471
15. C.R. Meier, R.G. Schlienger, M.E. Kraenzlin, B. Schlegel, and H. Jick HMG-CoA reductase inhibitors and the risk of hip fractures JAMA 283 2000 3205 3210
16. K.A. Chan, S.E. Andrade, M. Boles, D.S.M. Buist, G.A. Chase, and J.G. Donahue Inhibitors of hydroxymethylglutaryl-coenzyme a reductase and risk of fracture among older women Lancet 355 2000 2185 2188
17. P.S. Wang, D.H. Solomons, H. Mogun, and J. Avorn HMG-CoA reductase inhibitors and the risk of hip fracture in elderly patients JAMA 283 2000 3211 3216
18. L. Rejnmark, M.L. Olsen, S.P. Johnsen, P. Vestergaard, H.T. Sorensen, and L. Mosekilde Hip fracture risk in statin users - a population-based Danish case-control study Osteoporos. Int. 15 2004 452 458
19. T.P. Van Staa, S. Wegman, B. leufkens, and C. Cooper Use of statins and risk of fractures JAMA 285 2001 1850 1855
20. I.R. Reid, W. Hague, J. Emberson, J. Baker, A. Tonkin, and D. Hunt Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial Lancet 357 2001 509 512
21. T.R. Pedersen, and J. Kjekshus Statin drugs and the risk of fracture JAMA 284 2000 1921 1922
22. M. Sugiyama, T. Kodama, K. Konishi, K. Abe, S. Asami, and S. Oikawa Compactin and simvastatin, but not pravastatin, induce bone morphogenic protein-2 in human sarcoma cells Biochem. Biophys. Res. Commun. 271 2000 688 692
23. A.Z. LaCroix, J.A. Cauley, M. Pettinger, J. Hsia, D.C. Bauer, and J. McGowan Statin use, clinical fracture, and bone density in postmenopausal women: results from the women's health initiative observational study Ann. Intern. Med. 139 2003 97 104
24. D.C. Bauer, G.R. Mundy, S.A. Jama, D.M. Black, J.A. Cauley, and K.E. Ensrud Use of statins and fracture. Results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials Arch. Intern. Med. 164 2004 146 152
25. S.R. Cummings, M.C. Nevitt, W.S. Browner, K. Stone, K.M. Fox, and K.E. Ensrud Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group N. Engl. J. Med. 332 1995 767 773
26. D.M. Black, S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, and M.C. Nevitt Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
27. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, and B. Riggs Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
28. H. Burger, C.E. de Laet, P.L. van Daele, A.E. Weel, J.C. Witteman, and A. Hofman Risk factors for increased bone loss in an elderly population: the Rotterdam Study Am. J. Epidemiol. 147 1998 871 879
29. M.W. Schoofs, M.C. Sturkenboom, M. van der Klift, A. Hofman, H.A. Pols, and B.H. Stricker HMG-coA reductase inhibitors and the risk of vertebral fracture J. Bone Miner. Res. 19 2004 1925 1930
30. A. Montagnani, S. Gonnelli, C. Cepollaro, S. Pacini, M.S. Campagna, and M.B. Franci Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study Bone 32 2003 427 433
31. C.J. Edwards, D.J. Hart, and T.D. Spector Oral statins and increased bone-mineral density in postmenopausal women Lancet 355 2000 2218 2219
32. D.H. Solomon, J.S. Finkelstein, P.S. Wang, and J. Avorn Statin lipid-lowering drugs and bone mineral density Pharmacoepidemiol. Drug Saf. 14 2004 219 226
33. J.A. Pasco, M.A. Kotowicz, M.J. Henry, K.M. Sanders, and G.C. Nicholson Statin use, bone mineral density, and fracture risk Arch. Intern. Med. 162 2002 537 540
34. L. Rejnmark, N.H. Buus, P. Vestergaard, L. Heickendorff, F. Andreasen, and M.L. Larsen Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women J. Bone Miner. Res. 19 2004 737 744
35. D.J. Graham, J.A. Staffa, D. Shatin, S.E. Andrade, S.D. Schech, and La GrenadeL Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590
36. G. Hayem Statins and muscles: what price glory? Joint Bone Spine 69 2002 249 251
37. P. Chazerain, G. Hayem, S. Hamza, C. Best, and J.M. Ziza Four cases of tendinopathy in patients on statin therapy Joint Bone Spine 68 2001 430 433
38. AFSSAPS. Risque musculaire des statines Juin 2002.
39. B. Kwak, F. Mulhaupt, S. Myit, and F. Mach Statins as a newly recognized type of immunomodulator Nat. Med. 6 2000 1399 1402
40. C.J. Penney Statins in rheumatology J. Rheum 32 2005 17 19
41. M.R. Ehrenstein, E.C. Jury, and C. Mauri Statins for atherosclerosis - as good as it gets? N. Engl. J. Med. 352 2005 73 75
42. B.P. Leung, N. Sattar, A. Crilly, M. Prach, D.W. McCarey, and H. Payne A novel anti-inflammatory role for simvastatin in inflammatory arthritis J. Immunol. 170 2003 1524 1530
43. H. Konda, K. Hamasaki, K. Kubo, S. Tateishi, A. Yonezumi, and Y. Kanda Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis J. Rheumatol. 29 2002 2024 2026
44. C. Abud-Mendoza, H. de la Fuente, E. Cuevas-Orta, L. Baranda, J. Cruz-Rizo, and R. Gonzalez-Amaro Therapy with statins with refractory rheumatic diseases: a preliminary study Lupus 12 2003 607 611
45. D. McCarey, I. McInnes, R. Madhok, R. Hampson, O. Scherbakova, and I. Ford Trial of atorvastatin in rheumatoid arthritis (TARA): double blind, randomized placebo-controlled trial Lancet 363 2004 2015 2021
46. S. Lawman, C. Mauri, E.C. Jury, H.T. Cook, and M.R. Ehrenstein Atorvastatin inhibits autoreactive B cell activation and delays lupus development in new Zealand black/white F1 mice J. Immunol. 173 2004 7641 7646
47. B. Noel, and R.G. Panizzon Lupus-like syndrome associated with statin therapy Dermatology 208 2004 276 277
48. I.W. Graziadei, G.E. Obermoser, N.T. Sepp, K.H. Erhart, and W. Vogel Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis Lupus 12 2003 409 412
49. B. Noel, J.P. Cerottini, and R.G. Panizzon Atorvastatin-induced dermatomyositis Am. J. Med. 110 2001 670 671
50. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1999 115 126
51. E.T.H. Yeh CRP as a mediator of disease Circulation 109 Suppl II 2004 II11 II14
52. J.T. Willerson, and P.M. Ridker Inflammation as a cardiovascular risk factor Circulation 109 Suppl II 2004 II2 II10
53. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of the first cardiovascular events N. Engl. J. Med. 347 2002 1557 1565
54. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, and A. Rumley C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N. Engl. J. Med. 350 2004 1387 1397
55. J.K. Pai, T. Pischon, J. Ma, J.E. Manson, S.E. Hankinson, and K. Joshipura Inflammatory markers and the risk of coronary heart disease in men and women N. Engl. J. Med. 351 2004 2599 2610
56. P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, and C.H. McCabe C-reactive protein levels and outcomes after statin therapy N. Engl. J. Med. 352 2005 20 28
57. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, T. Crowe, W.J. Sasiela, and J. Tsai Statin therapy, LDL cholesterol, C-reactive protein, and coronary disease N. Engl. J. Med. 352 2005 29 38
58. V. Pasceri, and E.T.H. Yeh A tale of two diseases: atherosclerosis and rheumatoid arthrtitis Circulation 100 1999 2124 2126
59. M.M. Ward Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum. 44 2001 1467 1469
60. D.P.M. Symmons, M.A. Jones, D.L. Scott, and P. Prior Longterm mortality outcomes in patients with rheumatoid arthritis: early presenters continue to do well J. Rheumatol. 25 1998 1072 1077
61. F. Wolfe, D.M. Mitchell, J.T. Sibley, J.F. Fries, D.A. Bloch, and C.A. Williams The mortality of rheumatoid arthritis Arthritis Rheum. 37 1994 481 494
62. D.J. Watson, T. Rhodes, and H. Guess All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK general practice research database J. Rheum 30 2003 1196 1202
63. N.J. Goodson, N.J. Wiles, M. Lunt, E.M. Barrett, A.J. Silman, and D.P. Symmons Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients Arthritis Rheum. 46 2002 2010 2019
64. H. Maradit-Kremers, P.J. Nicola, C.S. Crowson, K.V. Ballman, and S.E. Gabriel Cardiovascular death in rheumatoid arthritis Arthritis Rheum. 52 2005 722 732
65. F. Wolfe, B. Freundlich, and W. Strauss Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis J. Rheumatol. 30 2003 36 40
66. I. Del Rincon, K. Williams, M.P. Stern, G.L. Freeman, and A. Escalante High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors Arthritis Rheum. 44 2001 2737 2745
67. D.H. Solomon, E.W. Karlson, E.B. Rimm, C.C. Cannuscio, L.A. Mandl, and J.E. Manson Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 2003 1303 1307
68. H. Maradit-Kremers, C.S. Crowson, P.J. Nicola, K.V. Ballman, V.L. Roger, and S.J. Jacobsen Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis Arthritis Rheum. 52 2005 402 411
69. G. Vaudo, S. Marchesi, R. Gerli, R. Allegrucci, A. Giordano, and D. Siepi Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity Ann. Rheum. Dis. 63 2004 31 35
70. R. Bergholm, M. Leirisalo-Repo, S. Vehkavaara, S. Mäkimattila, M.R. Taskinen, and H. Yki-Järvinen Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis Arterioscler. Thromb. Vasc. Biol. 22 2002 1637 1641
71. D. Hurlimann, A. Forster, G. Noll, F. Enseleit, R. Chenevard, and O. Distler Anti-tumor necrosis factor-a treatment improves endothelial function in patients with rheumatoid arthritis Circulation 106 2002 2184 2187
72. G.L. Burke, G.W. Evans, W.A. Riley, A.R. Sharrett, G. Howard, and R.W. Barnes Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults Stroke 26 1995 386 391
73. Y. Kumeda, M. Inaba, H. Goto, M. Nagata, Y. Henmi, and Furumitsu Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis Arthritis Rheum. 46 2002 1489 1497
74. I. Del Rincon, K. Williams, M.P. Stern, G.L. Freeman, D.H. O'Leary, and A. Escalante Association between atherosclerosis and markers of inflammation in rheumatoid arthritis and healthy subjects Arthritis Rheum. 48 2003 1833 1840
75. C. Aranow, and E.M. Ginzler Epidemiology of cardiovascular disease in systemic lupus erythematosus Lupus 9 2000 166 169
76. M. Petri, S. Perez-Gutthann, D. Spence, and M.C. Hochberg Risk factors for coronary disease in patients with systemic lupus erythematosus Am. J. Med. 93 1992 513 519
77. S. Manzi, E.N. Meilahn, J.E. Rairie, C.G. Conte, T.A. Medsger Jr., and L. Jansen-McWilliams Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study Am. J. Epidemiol. 145 1997 408 415
78. Y. Asanuma, A. Oeser, A.K. Shintani, E. Turner, N. Olsen, and S. Fazio Premature coronary-artery atherosclerosis in systemic lupus erythematosus N. Engl. J. Med. 349 2003 2407 2415
79. M.J. Roman, B.A. Shanker, A. Davis, M.D. Lockshin, L. Sammaritano, and R. Simantov Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus N. Engl. J. Med. 349 2003 2399 2406
80. N. Sattar, D.W. McCarey, H. Capell, and I.B. McInnes Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis Circulation 108 2003 2957 2963
81. M. Boers, M.T. Nurmohamed, C.J. Doelman, L.R. Lard, A.C. Verhoeven, and A.E. Voskuyl Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis Ann. Rheum. Dis. 62 2003 842 845
82. Y.B. Park, S.K. Lee, W.K. Lee, C.H. Suh, C.W. Lee, and C.H. Lee Lipid profiles in untreated patients with rheumatoid arthritis J. Rheumatol. 26 1999 1701 1704
83. C. Gorman, and D. Isenberg Atherosclerosis and lupus Rheumatol. 43 2004 943 945
84. Y.B. Park, H.K. Choi, M.Y. Kim, W.K. Lee, J. Song, and G.K. Kim Effect of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study Am. J. Med. 113 2002 188 193
85. R. Munro, E. Morrison, A.G. McDonald, J.A. Hunter, R. Madhok, and H.A. Capell Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis Ann. Rheum. Dis. 56 1997 374 377
86. E. Gauza, K. Gauza, U. Hanusch-Enserer, M. Etemad, A. Dunky, and K. Kostner Intravenous anti-TNF-a antibody therapy leads to elevated triglyceride and reduced LDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis Wien. Klin. Wochenschr. 114 2002 1004 1007
87. M. Vis, M.T. Nurmohamed, G. Wolbink, A.E. Voskuyl, M.H.M.T. de Koning, and R.J. van de Stadt Short term effects of Infliximab on the lipid profile in patients with rheumatoid arthritis J. Rheum. 32 2005 252 255
88. C. Popa, M.G. Netea, T. Radstake, J.W.M. Van der Meer, A.F.H. Stalenhoef, and P.L.C.M. van Riel Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis Ann. Rheum. Dis. 64 2005 303 305
89. P.G. Vlachoyiannopoulos, and M. Samarkos Peripheral vascular disease in antiphospholipid syndrome Thromb. Res. 114 2004 509 519
90. P.C. Souverein, A. Berard, T.P. Van Staa, C. Cooper, A.C.G. Egberts, and H.G.M. Leufkens Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study Heart 90 2004 859 865
91. L. Wei, T.M. MacDonald, and B.R. Walker Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease Ann. Intern. Med. 141 2004 764 770
92. I. Del Rincon, D.H. O'Leary, R.W. Haas, and A. Escalante Effect of glucocorticoids on the arteries in rheumatoid arthritis Arthritis Rheum. 50 2004 3813 3822
93. D.E. Ferrara, X. Liu, R.G. Espinola, P.L. Meroni, I. Abukhalaf, and E.N. Harris Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model Arthritis Rheum. 48 2003 3272 3279
94. AFSSAPS. Prise en charge thérapeutique des patients dyslipidémiques. Mars 2005.
95. M. Soubrier, D. Zerkak, and M. Dougados Traitement hypoliṕmiant au cours de la polyarthrite rhumatoïde. Une pŕvalence sous-estiḿe Rev. Rhum. 71 Suppl 2004 S921
96. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;16;106:388-91.
97. M. Soubrier, D. Zerkak, and M. Dougados Indications for LDL cholesterol lowering interest in rheumatoid arthritis (RA): an underestimated prevalence Arthritis Rheum. 50 Suppl 2004 S379
98. A. Al-Herz, S. Ensworth, K. Shojania, and J.M. Esdaile Cardiovascular risk factor screening in systemic lupus erythematosus J. Rheumatol. 30 2003 493 496
99. R.J. Edison, and M. Muenke Central nervous system and limb anomalies in case reports of first-trimester statin exposure N. Engl. J. Med. 350 2004 1579 1582